Literature DB >> 24803171

Hapten optimization for cocaine vaccine with improved cocaine recognition.

Muthu Ramakrishnan1, Berma M Kinsey, Rana A Singh, Thomas R Kosten, Frank M Orson.   

Abstract

In the absence of any effective pharmacotherapy for cocaine addiction, immunotherapy is being actively pursued as a therapeutic intervention. While several different cocaine haptens have been explored to develop anticocaine antibodies, none of the hapten was successfully designed, which had a protonated tropane nitrogen as is found in native cocaine under physiological conditions, including the succinyl norcocaine (SNC) hapten that has been tested in phase II clinical trials. Herein, we discuss three different cocaine haptens: hexyl norcocaine (HNC), bromoacetamido butyl norcocaine (BNC), and succinyl butyl norcocaine (SBNC), each with a tertiary nitrogen structure mimicking that of native cocaine which could optimize the specificity of anticocaine antibodies for better cocaine recognition. Mice immunized with these haptens conjugated to immunogenic proteins produced high titre anticocaine antibodies. However, during chemical conjugation of HNC and BNC haptens to carrier proteins, the 2β methyl ester group is hydrolyzed, and immunizing mice with these conjugate vaccines in mice produced antibodies that bound both cocaine and the inactive benzoylecgonine metabolite. While in the case of the SBNC conjugate, vaccine hydrolysis of the methyl ester did not appear to occur, leading to antibodies with high specificity to cocaine over BE. Although we observed similar specificity with a SNC hapten, the striking difference is that SBNC carries a positive charge on the tropane nitrogen atom, and therefore, it is expected to have better binding of cocaine. The 50% cocaine inhibitory concentration (IC50 ) value for SBNC antibodies (2.8 μm) was significantly better than the SNC antibodies (9.4 μm) when respective hapten-BSA was used as a substrate. In addition, antibodies from both sera had no inhibitory effect from BE. In contrast to BNC and HNC, the SBNC conjugate was also found to be highly stable without any noticeable hydrolysis for several months at 4 °C and 2-3 days in pH 10 buffer at 37 °C. © Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  TA-CD vaccine; addiction; antibody; benzoylecgonine; carrier protein; cocaine; hapten; mice; outer membrane protein complex; specificity; substance abuse; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24803171      PMCID: PMC4127111          DOI: 10.1111/cbdd.12326

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  28 in total

1.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

Review 2.  Vaccines against drug abuse.

Authors:  X Y Shen; F M Orson; T R Kosten
Journal:  Clin Pharmacol Ther       Date:  2011-11-30       Impact factor: 6.875

3.  Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine.

Authors:  M Pérez-Melgosa; H D Ochs; P S Linsley; J D Laman; M van Meurs; R A Flavell; R K Ernst; S I Miller; C B Wilson
Journal:  Eur J Immunol       Date:  2001-08       Impact factor: 5.532

4.  Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.

Authors:  J J Donnelly; R R Deck; M A Liu
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

Review 5.  Substance abuse vaccines.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 6.  Vaccines for cocaine abuse.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Thomas R Kosten
Journal:  Hum Vaccin       Date:  2009-04-20

7.  Concentrations of cocaine and its major metabolite benzoylecgonine in blood samples from apprehended drivers in Sweden.

Authors:  A W Jones; A Holmgren; F C Kugelberg
Journal:  Forensic Sci Int       Date:  2007-12-31       Impact factor: 2.395

8.  Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure.

Authors:  Sabina H L de Villiers; Nina Lindblom; Genadiy Kalayanov; Sandra Gordon; Ivan Baraznenok; Anna Malmerfelt; Monica M Marcus; Anette M Johansson; Torgny H Svensson
Journal:  Vaccine       Date:  2010-01-07       Impact factor: 3.641

9.  A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

Authors:  Eugene C Somoza; Douglas Winship; Charles W Gorodetzky; Daniel Lewis; Domenic A Ciraulo; Gantt P Galloway; Scott D Segal; Michael Sheehan; John D Roache; Warren K Bickel; Donald Jasinski; Donnie W Watson; Steven R Miller; Peggy Somoza; Theresa Winhusen
Journal:  JAMA Psychiatry       Date:  2013-06       Impact factor: 21.596

10.  A second-generation vaccine protects against the psychoactive effects of cocaine.

Authors:  M R Carrera; J A Ashley; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  7 in total

1.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

Review 2.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

3.  Suppression of Cocaine-Evoked Hyperactivity by Self-Adjuvanting and Multivalent Peptide Nanofiber Vaccines.

Authors:  Jai S Rudra; Ye Ding; Harshini Neelakantan; Chunyong Ding; Rajagopal Appavu; Sonja Stutz; Joshua D Snook; Haiying Chen; Kathryn A Cunningham; Jia Zhou
Journal:  ACS Chem Neurosci       Date:  2016-03-08       Impact factor: 4.418

4.  Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.

Authors:  Cody J Wenthur; Xiaoqing Cai; Beverly A Ellis; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-07-05       Impact factor: 2.823

Review 5.  Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.

Authors:  Fang Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2019-02-06       Impact factor: 4.530

6.  Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine.

Authors:  Leonardo da Silva Neto; Angélica Faleiros da Silva Maia; Adriana Martins Godin; Paulo Sérgio de Almeida Augusto; Raissa Lima Gonçalves Pereira; Sordaini Maria Caligiorne; Rosemeire Brondi Alves; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Gisele Assis Castro Goulart; Felipe Terra Martins; Maila de Castro Lourenço das Neves; Frederico Duarte Garcia; Ângelo de Fátima
Journal:  J Adv Res       Date:  2021-09-13       Impact factor: 12.822

7.  Are therapeutic vaccines an answer to the global problem of drug and alcohol abuse?

Authors:  Dick B S Brashier; Ashok Kumar Sharma; Neha Akhoon
Journal:  Indian J Pharmacol       Date:  2016 Sep-Oct       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.